Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape
Iseult M. Browne, Monica Esteban Garcia, Alicia F. C. Okines · 2026
Read Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape by Iseult M. Browne, Monica Esteban Garcia, Alicia F. C. Okines (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13591336.txt.
Description
Iseult Browne, Monica Esteban Garcia, and Alicia Okines review treatment for metastatic triple negative breast cancer in this 2026 paper. This cancer lacks estrogen, progesterone, and HER2 receptors, which removes many drug targets. It kills a disproportionate share of breast cancer patients. The last decade brought major new options, though.
Immune checkpoint drugs and antibody drug conjugates changed the standard of care. PARP inhibitors serve patients with certain inherited mutations. The review weighs each class, its biomarkers, and its resistance paths. Tumor biology and the surrounding microenvironment are covered as well. A framework for choosing and sequencing treatments by biomarker is proposed. The aim is practical guidance in a fast moving field.
Catalog record
| CREATOR | Iseult M. Browne, Monica Esteban Garcia, Alicia F. C. Okines |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 143 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |